Cytori Therapeutics, Inc. (CYTX)
-NasdaqGM 2.33 
0.01(0.43%) 4:00PM EDT
| Prev Close: | 2.32 |
|---|
| Open: | 2.32 |
|---|
| Bid: | N/A |
|---|
| Ask: | 2.35 x 1300 |
|---|
| 1y Target Est: | 6.63 |
|---|
| Beta: | 2.28 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 2.30 - 2.34 |
|---|
| 52wk Range: | 2.21 - 4.93 |
|---|
| Volume: | 205,740 |
|---|
| Avg Vol (3m): | 237,708 |
|---|
| Market Cap: | 156.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013at Seeking Alpha(Mon, May 20)
- CYTORI THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Energy And Biotechs With Recent Earnings Catalystsat Seeking Alpha(Mon, May 13)
- Medivation Loss Narrower Than ExpectedZacks(Mon, May 13)
- CYTORI THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Cytori Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Cytori Reports First Quarter 2013 Business and Financial ResultsBusiness Wire(Thu, May 9)
- CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Thu, May 9)
- Q1 2013 Cytori Therapeutics Earnings Release - 4:05 pm ETCCBN(Thu, May 9)
- Osiris Loss In-Line with ExpectationsZacks(Wed, May 8)
- Safe Stem Cell Therapy for Healing Is Still a Strong Betat Motley Fool(Tue, May 7)
- Cytori to Webcast First Quarter Financial Results on May 9Business Wire(Thu, May 2)
- Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacksat Seeking Alpha(Tue, Apr 23)
- North Korean Threats And The Cytori - BARDA Stem Cell Collaborationat Seeking Alpha(Tue, Apr 16)
- 4 Health Care Stocks Under $10 to Watchat TheStreet(Tue, Apr 16)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 9.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.44 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cytori Therapeutics, Inc., a cell therapy company, engages in developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular diseases, burns, and other soft tissue injuries.
View More